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Summary 
In several pedigrees of early onset familial Alzheimer’s 
disease (FAD), point mutations in the (I-amyloid pre- 
cursor protein (APP) gene are genetically linked to the 
disease. This finding implicates APP in the pathogene- 
sis of Alzheimer’s disease in these individuals. To under- 
stand the in vivo function of APP and its processing, we 
have generated an APP-null mutation in mice. Homoq- 
gous APP-deficient mice were viable and fertile. How- 
ever, the mutant animals weighed 15%-20% less than 
age-matched wild-type controls. Neurological evalua- 
tion showed that the APPdeficient mice exhibited a de- 
creased locomotor activity and forelimb grip strength, 
indicating a compromised neuronal or muscular func- 
tion. In addition, four out of six homozygous mice 
showed reactive gliosis at 14 weeks of age, suggesting 
an impaired neuronal function as a result of the APP- 
null mutation. 
Introduction 
Alzheimer’s disease (AD) is a neurodegenerative disorder 
that disproportionately affects the population over 65 
years of age. It is characterized pathologically by the pres- 
ence of senile plaques, neurofibrillary tangles, and exten- 
sive neuronal cell loss. Senile plaques are extracellular 
deposits of heterogeneous substances of which the major 
component is a 39-43 amino acid peptide referred to as 
&amyloid peptide or A6 (Glenner and Wong, 1964). The 
4 kDa A6 peptide is derived by proteolytic cleavage of a 
larger 5-amyloid precursor protein (APP; Kang et al., 
1987). APP is an integral membrane glycoprotein con- 
sisting of an extracellulardomain, a single transmembrane 
domain, and a short cytoplasmic tail. About two-thirds of 
the A6 peptide is extracellular, and the remaining se- 
quence is embedded in the membrane (Selkoe, 1993). 
The APP gene, located on the long arm of chromosome 
21 (Goldgaber et al., 1987) spans approximately 400 kb 
(at least 18 exons; Yoshikai et al., 1990; Lamb et al., 1993). 
Alternative splicing generates APP mRNAs encoding sev- 
eral isoforms that range from 365 to 770 amino acid resi- 
dues (Kosik, 1993). The major A5 peptides encoding pro- 
teins measure 695,751, and 770 amino acids (referred to 
as APP695, APP751, and APP770). APP751 and APP770 
contain a domain homologous to the Kunitz-type serine 
protease inhibitors (KPls; Kitaguchi et al., 1988; Ponte et 
al., 1988) that is absent in APP695. APP695 is expressed 
predominantly in neurons. APP751 and APP770 can be 
detected in all tissues examined (Neve et al., 1988). APP 
is also expressed during early mouse embryonic develop- 
ment (Fisher et al., 1991). 
APP undergoes at least three different processing path- 
ways. In the constitutive secretory pathway, the molecule 
is cleaved within the A5 region, thus preventing 5-amyloid 
formation (Esch et al., 1990; Sisodia et al., 1990). Alterna- 
tively, APP can be internalized from the cell surface and 
targeted to the endosomal-lysosomal compartment, where 
APP fragments containing the intact A6 are generated 
(Golde et al., 1992; Haass et al., 1992). Finally, the A6 
peptide is normally secreted from cultured cells and is 
found in cerebrospinal fluid (CSF) of patients with AD as 
well as in that of healthy individuals (Selkoe, 1993). The 
functions of APP and A5 in vivo are still uncertain. APP has 
been implicated as a growth factor in fibroblast cultures 
(Saitoh et al., 1989) as a mediator of cell adhesion and 
neurite outgrowth (Schubert et al., 1989; Milward et al., 
1992) as a regulator of intraneuronal calcium (Mattson 
et al., 1993) and as a neuronal receptor regulating the 
GTP-binding protein G, (Nishimoto et al., 1993). The A6 
peptide has been shown to have neuroprotective and neu- 
rotoxic actions, dependent on the cell line and protein 
preparations tested (Kosik and Coleman, 1992). The fact 
that intraneuronal expression of A6 peptide in transgenic 
mice leads to neurodegeneration and apoptosis strongly 
suggests that A6 is neurotoxic in vivo (LaFerla et al., 1995). 
The KPI domain may serve a role in regulating protein 
half-life (Van Nostrand et al., 1990; Miyazaki et al., 1993). 
Abnormal regulation and misprocessing of APP may 
contribute to AD. In Down’s syndrome (DS) patients, the 
APP gene is overexpressed, owing to the presence of an 
extra copy of a portion of chromosome 21 encoding the 
APP gene. Individuals with DS who live into their thirties 
invariably develop early onset AD pathology (Mann, 1989) 
suggesting that an increase in APP gene dosage may con- 
tribute to AD in these patients. In addition, five different 
mutations have been identified in the human APP (hAPP) 
gene, linking the hAPP gene to early onset familial AD 
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Figure 1. Generation of APP-Deficient Mice 
(A) Targeted disruption of the APP gene in ES cells. The targeting 
vector (pHZ 038) contains the following, from left to right: a 1.4 kb 
segment preceding the APP promoter (hatched 5’ rectangle); a PGK- 
neo expression cassette inserted in an orientation opposite to that of 
the APP gene; a fragment of 7.1 kb homologous to the first intron of 
the APP gene (hatched 3’rectangle); and an MU-TK gene for negative 
selection (Mansour et al., 1988; labeled HSV-TK, shown as a closed 
box). Probes used (shown as black boxes below the physical map) 
for detecting a targeted event were the following: a 1 .O kb Xbal-Bglll(5’ 
probe); a 0.8 kb Bglll-Ncol(3’-probe); and the neo sequence. Digestion 
with the restriction endonuclease EcoRl was used to separate the 
wild-type and the targeted APP alleles. R, EcoRI; X, Xbal; B, Bglll; 
N, Ncol. Pr, mouse APP promoter; El, exon 1 of the mouse APP gene; 
PGK, phosphoglycerate kinase promoter. 
(B) Southern blot analysis of representative offspring from heterozy- 
gous matings. Genomic DNA isolated from the tails of P-week-old pups 
generated from crosses of heterozygous mice was digested with 
EcoRI, transferred to membranes, and hybridized with the 5’ probe. 
(+I+), wild-type; (+I-), heterozygotes; (-I-), homozygous APP- 
deficient mice. 
(C) APP gene expression. Total RNA (20 ug) from wild-type (+I+), 
heterozygous (+I-), and homozygous (-I-) APP mice was isolated 
(two mice each) from brain and kidney (data not shown) by using the 
RNAzol B method (Biotecx Laboratories, Incorporated) and hybridized 
with the full-length APB95 cDNA sequence. APP mRNA is absent in 
(-I-) mice in both tissues. Lower panel, mouse 3-actin cDNA hybridiza- 
tion for loading control. 
lies (Mullan and Crawford, 1993). These affected families 
provide the strongest evidence yet for the notion that APP 
processing and A6 peptide accumulation serve a central 
role in AD progression. Indeed, in vitro studies have shown 
that these mutations alter APP processing to generate 
increased levels of AD (Citron et al., 1992; Cai et al., 1993) 
or to produce longer forms of A6 peptides, which are poten- 
tially more amyloidogenic (Suzuki et al., 1994). 
We have generated a complete deficiency of APP in 
mice by homologous recombination in embryonic stem 
(ES) cells. Neither APP mRNA nor protein can be detected 
in the mutant animals, and the mice show reactive gliosis 
and behavioral abnormalities. 
Results 
Generation of APP-Deficient Mice 
We inactivated the mouse APP gene by deleting a 3.8 kb 
sequence encoding its promoter (Izumi et al., 1992) and 
first exon, which encodes the ATG translation initiation 
codon and the signal peptide of the APP (Figure 1 A). The 
linearized targeting vector (pHZ 038) was electroporated 
into AB2.1 ES cells, and transfected cells were selected 
in the presence of G418 and 1-(2’deoxy, 2’-fluoro+&arabii 
nofuranosyl)&iodouracil (FIAU). A 4.4fold enrichment was 
achieved by FIAU counter selection as compared with G418 
selection alone. Double-resistant colonies were expanded 
and screened by a mini-Southern blot protocol (Ramirez- 
Solis et al., 1992). A total of six targeted clones were identi- 
fied from 193 double-resistant colonies (a targeted recom- 
bination versus random integration event of 1 in 140). The 
5’ and 3’ probes used for Southern blot analysis of the 
targeted locus immediately flanked the targeting se- 
quences (Figure 1A). The expected polymorphic EcoRl 
restriction enzyme fragments were detected for the wild- 
type (9.0 kb) and the targeted (6.5 kb) APP alleles with 
the 5’ probe (Figure 16) and 3’ probe (data not shown). 
A total of seven male chimeras were produced from two 
of the ES clones (numbers 76 and 174), with ES cell contri- 
butions ranging from 60% to 1000/o, as judged by the per- 
centage of agouti coat color in the chimeric mice. Success- 
ful germline transmission of ES cells was achieved with 
both clones, and approximately 50% of the agouti pups 
contained the disrupted APP allele. Heterozygous mice 
were indistinguishable from their normal littermates. To 
produce mice homozygous for the disrupted APP gene, 
cross-matings between heterozygous mice were set up. 
Normal litter sizes were observed, and the genotypes of 
the resulting pups were analyzed (Figure 16). Of 87 mice 
analyzed at 2 weeks of age, 30 (34%) were wild type 
(+I+), 36 (41%) were heterozygous (+I-), and 21 (24%) 
were homozygous (-I-) for the mutated APP allele, repre- 
senting a normal 1:2:1 Mendelian inheritance of the mu- 
tated APP allele. This result ruled out an essential function 
of APP in mouse embryogenesis. The homozygous APP 
knockout mice appeared normal and healthy up to 6 
months of age. 
Molecular Characterization of APP-Deficient Mice 
To determine whether the APP gene is completely inacti- 
vated following the deletion of its promoter and first exon, 
Northern blot analysis was performed to determine APP 
mt?NA levels with brain and kidney RNA, using APP695 
cDNA as a probe. APP mRNA could not be detected in 
mice homozygous for the targeted allele. The APP mes- 
sage was reduced by approximately 50% in the heterozy- 
gous mice compared with amounts in wild-type controls 
(Figure 1 C). Western blot analysis using an APP-specific 
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Figure 2. Astrogliosis in the Brains of APP-Null Mice 
Representative photomicrograph of GFAP-immunostained coronal 
brain sections through the hippocampus ([A], +I+; [B], -I-), entorhinal 
cortex ([Cl, +I+; [D], -I-) and parietal cortex ([El, +I+; [F], -I-) of a 
wild-type (+I+) and an APP-deficient (-I-) mouse. CC, cerebral cortex; 
CAI, hippocampal field 1; ML, molecular layer. 
antibody (CT1 5) could not detect any APP protein in brain 
and other tissues of the homozygous APP knockout 
mouse (data not shown). 
In situ hybridization was carried out with different 
%-labeled oligonucleotide probes, each specific for the 
mouse APP695, APP751, and APP770. Although APP 
mRNAwasexpressed throughout the brain in thewild-type 
mouse, it could not be detected in any brain region ana- 
lyzed in the homozygous (-I-) APP knockout mouse (data 
not shown). We can thus exclude that local regions of 
gene expression, below the sensitivity of Northern blot 
analyses, were present in the brain. 
Neuroanatomical and Histopathological Analysis 
of APP-Deficient Mice 
Since APP is expressed at the highest level in the brain, 
immunohistochemical studies were performed on two 
6-week-old and two lCweek-old APP-null mice to check 
for developmental or other neuroanatomical changes. Im- 
munostaining of brain sections from wild-type animals with 
the N-terminal APP antibody 22Cll showed normal homo- 
geneous APP immunoreactivity in neurons in all areas of 
the cortical mantle and in the hippocampus and cerebel- 
lum, which have the highest densities of APP staining 
(data not shown). lmmunoreactive APP neurons could not 
be detected in a total of four homozygous APP-null mice 
in any of the above outlined brain regions (data not shown). 
Hematoxylin- and eosin-stained brain sections from these 
APP-null mice did not reveal evidence for cellular abnor- 
malities in cortical, hippocampal, or cerebellar neurons in 
terms of swelling, atrophy, increase in basophilic material, 
or granulovacuolations (data not shown). 
When the above mice and four additional mice at 14 
weeks of age were stained with antibodies for the glial 
fibrillary acidic protein (GFAP), four out of six homozygous 
mutants showed reactive gliosis (Figure 2). In the brains 
of wild-type animals, a low level of GFAP immunoreactivity 
Figure 3. Neurological Evaluation of APP-Deficient Mice 
(A) Reduced forelimb gripstrength in homozygous APP knockout mice 
(p < 0.05) (males, n = 6; females, n = 7). (+I+), wild-type controls; 
(-I-), homozygous APP-null mice. See Experimental Procedures for 
details. 
(8) Reduced locomotor activity in APP homozygous knockout mice 
(p < 0.001). The spontaneous motor activity of APP-deficient mice 
([-I-], n = 8 males and 7 females) and their age- and sex-matched 
controls ([+/+I, n = 6 males and 7 females) are shown at successive 
6 min time intervals during the 60 min session. 
was principally localized in the hippocampus and layer 1 
of the cerebral cortex (Figures 2A, 2C, and 2E). In contrast, 
brain sections from APP-null mice showed greatly en- 
hanced GFAP immunoreactivity and typical reactive 
astrocytes with thicker and more numerous processes in 
the hippocampus and various parts of the neocortex (Fig- 
ures2B, 2D, and 2F). In the hippocampus, extensive astro- 
gliosis was seen in the CA1 region and in the molecular 
layer (ML), while in the neocortex, reactive gliosis was 
observed throughout the cortical layers. The onset of reac- 
tive gliosis may be age dependent, since we had not ob- 
served this in younger animals. However, a detailed time 
course study has to be performed to determine the age 
of onset. 
A total of six knockout mice and four controls (10 weeks 
old) were also processed for a detailed histopathological 
evaluation of brain and other tissues. A summary of the 
tissues examined appears in the Experimental Proce- 
dures in the section describing gross and microscopic 
analysis. Abnormal structures could not be found in any 
of the tissues examined in the APP-null mice. 
Neurological Evaluation of APP-Deficient Mice 
Although homozygous APP mutant mice were apparently 
healthy and fertile, the body weight of both males and 
females was 150/o-20% less at all agescompared with that 
of their age-matched controls. For example, at 9 weeks of 
age, the average body weights of male and female wild- 
type mice were 26.7 f 1.1 g and 23.6 f 0.9 g, respec- 
tively, while the corresponding APP-deficient mice mea- 
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Figure 4. Quantitative RT-PCR Analysis of APP Homologs 
Hemibrain RNA from wild-type ([+I+], lanes l-4) heterozygous 
([+/-I, lanes 5-6) and homozygous ([-/-I, lanes 9-l 2) APP knockout 
mice were reverse transcribed and PCR amplified at 16 (lanes 1, 5, 
and 9) 20 (lanes 2, 6, and lo), 22 (lanes 3, 7, and 1 l), and 24 (lanes 
4,6, and 12) cycles, respectively. The NF-L was used as amplification 
control. Control plasmids for APLPl (lane 13) APLP2 (lane 14) and 
APP (lane 15) were also PCR amplified as molecular weight standards, 
which show sizes of 500 bp, 150 bp, and 250 bp. respectively. 
sured 23.0 f 0.3 g and 18.3 f 0.3 g, respectively (n = 
10 per sex group). A group of eight male and seven female 
knockout mice and the same number of age- and sex- 
matched controls were subjected for preliminary neurolog- 
ical examinations. 
Determination of the forelimb grip strength of both the 
male and female knockout mice showed a significantly 
reduced grip strength compared with that of age- and sex- 
matched controls (Figure 3A; p < 0.05). The locomotor 
activity was measured as the total number of beam breaks 
in successive 6 min intervals for a total of 60 min. Since 
sex had no effect on these data, (p = 0.203), the data 
were collapsed across this variable. The APP-deficient 
mice showed a decreased locomotor activity compared 
with that of wild-type controls (Figure 38; p < 0.001). The 
total activity in the 60 min measurement for the control 
and APP knockout mice measured 660 f 54 beam breaks 
and 410 f 52 beam breaks, respectively. 
Expression of APP Homologs in APP 
Knockout Mice 
Two APP homologs, amyloid precursor-like protein 1 
(APLPl) and APLP2, have been identified in mouse and 
human (Wasco et al., 1992; Wasco et al., 1993; Slunt et 
al., 1994). The homologssharesignificant similarityintheir 
amino acid sequence, and several potentially functional 
domains are conserved. Like APP, both members of the 
APP family are expressed at high levels in the brain. The 
expression pattern of APLPP in the brain is similar to that 
of APP (Slunt et al., 1994). Therefore, the expression of 
APP homologs could theoretically compensate for the loss 
of the APP in the mutant mice. Direct evidence for this 
could not be obtained, since quantitative reverse transcrip- 
tion-polymerase chain reaction (RT-PCR) analysis of 
RNA levels of both homologs did not reveal significant 
differences in APLPl or APLP2 expression when com- 
pared among the wild-type, heterozygous, and homozy- 
gous mice (Figure 4). This result was further confirmed 
by Northern blot and in situ hybridization analysis (data 
not shown). 
Inactivation of the 400 kb APP gene, which undergoes 
alternative splicing, requires a careful design of the tar- 
geting vector to assure that an APP-null mutation can be 
generated. We chose to delete the APP promoter and first 
exon, with the assumption that the mutation would prevent 
APP gene transcription. If an alternative promoter and 
ATG translation initiation codon were used, transport of 
the protein to the membrane should be impaired, since 
the signal peptide was deleted. As a result, we generated 
a complete deficiency for APP at the mRNA and protein 
levels. Targeting the promoter and ATG translation initia- 
tion codon may serve as an approach to inactivate rela- 
tively large genes for which a deletion of the entire gene 
is impractical. 
In this report, we show that the APP-deficient mice were 
15%-20% underweight compared with age-matched con- 
trols, exhibited behavioral abnormalities, and exhibited 
significant reactive astrocytosis. Reactive gliosis occurs 
in many disease states and in response to neuronal injury 
(Eddleston and Mucke, 1993). The fact that four of six 
homozygous APP-deficient mice showed reactive gliosis 
at 14 weeks of age suggests that an impairment of neu- 
ronal function may occur as a result of the loss of APP. 
Indeed, APP and its derivatives have been shown to be 
involved in the regulation of neurite outgrowth through 
interactions with neuronal cell adhesion molecules and 
extracellular matrix proteins (Koo et al., 1993; Small et al., 
1993,1994) and through the regulation of intracellular Cap+ 
levels (Mattson et al., 1993). However, since APP is also 
expressed in nonneuronal cells and is involved in numer- 
ous extraneuronal activities in vitro (Mattson et al., 1993), 
and since we did not observe any neuronal cell damage or 
loss in the brains of APP-deficient mice, the mechanisms 
responsible for the reactive gliosis in these mice are not 
clear at present. 
Decreased body weight in the mutant animals correlated 
with a decreased food and water intake. Wild-type animals 
of varying ages and weights show similar grip strength 
and locomoter activity, thus indicating that body weight is 
not a major determinant of these behavioral parameters 
(data not shown). These results indicate that neuronal or 
muscular function may be compromised in the mutant ani- 
mals. These findings appear consistent with published evi- 
dence that APP may play a role in the process of nerve 
and muscle degeneration and regeneration: increased ex- 
pression of APP mRNA has been shown in motor neurons 
taken from rats following peripheral nerve axotomy (Sola 
et al., 1993) and in regenerating human muscle fibers from 
patients with neuromuscular diseases (Sarkozi et al., 
1994). 
APP is conserved among mammalian species (Shivers 
et al., 1988), and APP homologs have been identified in 
human (APLP7, APLP2), mouse (APLP7, APLP2), Dro- 
sophila melanogaster (Appl), and Caenorhabditis elegans 
@p/-l) (Rosen et al., 1989; Daigle and Li, 1993). These 
APP homologs lack the A8 region. The conservation 
among members of the APP gene family outlines that they 
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may be functionally related. indeed, the behavioral deficit 
in Drosophila containing a deletion of its APP homolog 
(Appl) can be partially rescued by the hAPP695 (Luo et 
al., 1992). Mutant mice with a modified APP (a deletion 
of exon 2) showed behavioral deficits, the result of which 
was published during the course of preparation of this 
manuscript (Mtiller et al., 1994). 
A comparison of the APP-null mice described here with 
those described by Miller et al. (1994) highlights unique 
aspects of the role of APP. First, the ability to maintain a 
normal APP-null litter size shows that the murine APP is 
either dispensable for development, or that the APP homo- 
logs compensate for the loss of APP. Second, in contrast 
with the APP exon 2 deletion mice generated by Miiller 
et al. (1994), approximately 65% of the APP-null mice over 
three months of age described here developed reactive 
gliosis. This could argue for a partial retention of function 
in the APP exon 2 deletion, preventing reactive gliosis. 
Third, the modified APP described by Miller et al. (1994) 
in some instances resembles the null mutation described 
here, showing significant though less severe reductions 
in body weight and locomotor activity, again indicating a 
partial rescue of the APP-null phenotype in the exon 2 
deletion mutant. Fourth, agenesis of the corpus callosum 
could not be detected in the APP-null mice, although mice 
of the same 129/Sv and C57BU6 hybrid genetic back- 
ground were used in both studies. Given that the APP 
exon 2 deletion mouse exhibits a separate phenotypic 
change with respect to corpus callosum development, this 
mutant protein has a distinct dominant effect, which may 
also have affected other aspects of neuronal development 
and function. 
In attempts to generate a murine model of AD, transgenic 
mice have been produced that express various forms of 
the hAPP gene (Price and Sisodia, 1994). Recently, suc- 
cessful AD-like neuropathology was reported in mice over- 
expressing a mutant form of the hAPP (V717F) gene 
(Games et al., 1995). A very high level of expression of 
hAPP was required to produce a mouse with AD-like neu- 
ropathology. This does not reflect the APP level in AD 
patients, and it is unclear whether overexpression of APP 
itself or B-amyloid plaque deposition is responsible for 
some of the pathology seen in these mice. Indeed, synap- 
tic loss can occur by overexpressing hAPP alone without 
plaque formation (Mucke et al., 1994). The requirement 
for a high level of expression of hAPP in transgenic mice 
may be explained by, among other factors, interference 
from the endogenous mouse APP, which has three amino 
acid differences in the AP region compared with human 
AD. APP-deficient mice may therefore serve as a valuable 
strain for insertion of the hAPP gene in our efforts to gener- 
ate mouse models of AD, mimicking human physiological 
conditions. 
Experimental Procedures 
Construction of the APP-Targeting Vector 
The APP promoter region was isolated from a 129 mouse library by 
using a 1 .O kb Hindlll-Pvull fragment from the APP promoter as a 
probe (Izumi et al., 1992). The targeting vector was constructed by 
ligating a 1.4 kb Bglll-Xhol fragment from the 5’ portion of the APP 
promoter and a 7.1 kb Xhol-Bglll fragment from the 3’portion of exon 
1. A 1.5 kb Xhol-Sall PGK-neo cassette (Ramirez-Solis et al., 1993) 
was inserted at the site of the deletion. The final vector was made by 
ligating the 2 kb Xhol fragment of pMC-TK (Mansour et al., 1988) to 
the 3’ end of the 7.1 kb targeting arm. 
Gene Targeting in Murlne ES Cells 
The targeting vector was linearized by digestion with Not1 prior to 
electroporation, leaving the pKS backbone attached to the end of the 
TK gene. AB2.1 cells (1 x 103 (pg14) and 25 pg of linear DNA were 
resuspended in phosphate-buffered saline and used for one electro- 
poration, which was carried out by use of a Bio-Rad Gene Pulser 
apparatus at 230 V and 500 vF. The cells were plated onto five 90 
mm dishes with y-irradiated SNL76/7 feeder cells. 6418 (200 &ml 
of active ingredient) and FIAU (0.4 PM) were applied 24 hr and 48 hr 
later, respectively. The double-resistant colonies were picked 10 days 
after G418 selection and subjected to mini-Southern blot analysis as 
previously described (Ramirez-Solis et al., 1992). 
Blastocyst InjectIon and Mouse Breedlng 
Targeted APP ES clones were injected into C57BU6J (Jackson Labo- 
ratories) recipient blastocysts by using techniques described pre- 
viously (Bradley, 1987). The injected embryos were reimplanted into 
the uteri of day 3 pseudopregnant Tac:SW (fBR, Taconic) mice and 
allowed to develop to term. The male chimeras were bred with C57BU 
6J females to assess their potential for germline colonization, which 
was determined by the presence of agouti pups in the offspring. The 
(+/+) and (-I-) APP-null breeding colonies were housed in a virus 
antibody-free (VAF) facility. The care for animals was conducted as 
approved by the Institutional Animal Care and Use Committee of Merck 
and Company, Incorporated. 
Initial Neurological Evaluation 
A blind study was carried out to determine forelimb grip strength and 
locomotor activity. The grip strength apparatus consisted of a 30 mm 
metal equilateral triangle (3 mm thickness) secured to a strain gauge 
transducer (Pioden Controls. Limited). The transducer was connected 
to an amplifier (Micro Movement, Limited), which in turn was connected 
to a chart recorder (Pharmacia LKB, model Brommo 2210). To mea- 
sureforelimbgrip strength, micewere held bythetail until theygrasped 
the metal triangle with both forepaws. The animal was then gently 
pulled away from the transducer, and the maximum force generated 
was recorded. Three successive readings were taken for each mouse. 
Locomotor activity measurements were performed with mice placed 
in individual activity cages (230 mm x 280 mm x 210 mm). The walls, 
floor, and ceiling were lined with wire mesh lo allow climbing all around 
the cage. Each cage was equipped with four parallel infrared beams 
that traversed the front and the back of the cage at floor and ceiling 
level. Total activity was measured by adding together the number of 
times each of the four beams was broken. 
The data were analyzed by using analysis of variance (ANOVA) 
followed by Newman-Keuls’ multiple comparison test. Analysis of grip 
strength was performed by using one-way ANOVA; locomotor activity 
was analyzed by three-way ANOVA using group, sex, and time as 
factors; and group differences were determined by one-way ANOVA. 
Quantltatlve RT-PCR Analysis of APLPl 
and APLPZ Expression 
RNA was prepared from mouse brain by homogenizing the tissue in 
guanidinium isothiocyanate and centrifugation through a CsCl cush- 
ion. From each RNA preparation, 2 pg was reverse transcribed in the 
presence of 50 pmol of random hexamer primers (Pharmacia, and 
Reverse Transcriptase from Bethesda Research Laboratories). For 
each sample, four tubes each containing one tenth of the RT mixture 
(equivalent to 200 ng of RNA) were subjected to PCR with B’-end 
=P-labeled APP/APLP sense primer (0.5 pmol), APP/APLP antisense 
primer at 50 WM. and neurofilament L (NF-L) oligos at 20 PM. The 
annealing temperature was 58%. The tubes were removed at 18,20, 
22, and 24 cycles. Previous results had shown that amplification is 
constant over this cycling range (Slunt et al., 1994). For each control, 
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0.5 ng of plasmid template was used, and the PCR was performed 
for20 cycles. Each reaction was subjected to phenol-chloroform ex- 
traction, and the PCR productswere precipitated with ammonium ace- 
tate and ethanol. Resulting PCR products were subsequently digested 
with BamHI-Hindlll-Xhol and fractionated on 2% agarose gels. Gels 
were dried and exposed to X-ray film. The sequences of the oligo 
primers for PCR can be obtained on request. 
Gross and Microscopic Analyses 
Mice were anesthetized with lsoflurane via an open drop method in 
an enclosed container. While the animals were anesthetized, blood 
was removed via cardiocentesis, and mice were returned to the con- 
tainerwith lsofluraneuntil euthanized. Miceweresubjected todiagnos- 
tic necropsies, and all tissues were fixed in 10% buffered formalin. 
Bones were decalcified by use of formic acid. Sections of the following 
tissues were prepared by routine methods and stained with hematoxy- 
lin and eosin: salivary gland, tongue, esophagus, stomach, small intes- 
tine, large intestine, liver, gall bladder, pancreas, adrenal gland, thy- 
roid gland, parathyroid gland, pituitary gland, kidney, urinary bladder, 
ovary, uterus, vagina, testis, epididymis, seminal vesicle, prostate 
gland, bulbourethral gland, penis, preputial gland, skin, mammary 
gland, lung, nasal turbinates, heart, aorta, spleen, lymph node, thy- 
mus, skeletal muscle, bone, bone marrow, brain (including cerebral 
cortex, subcortical white matter, cerebellum, pans, and corpus callo- 
sum), cervical spinal cord, sciatic nerve, eye (including optic nerve), 
harderian gland, and brown adipose tissue. 
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